Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cell therapies targeting solid tumor cancers. Its core technology cen... Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative cell therapies targeting solid tumor cancers. Its core technology centers on tumor infiltrating lymphocyte (TIL) therapy, which leverages a patient's own immune cells to attack a wide range of cancer types, including metastatic melanoma, cervical cancer, non-small cell lung cancer, and several others. The company’s lead marketed product, Amtagvi, is a tumor-derived autologous T cell immunotherapy for adult patients with unresectable or metastatic melanoma, while its pipeline features therapies under investigation for additional tumor types and blood cancers. Iovance is recognized for its proprietary cell therapy platforms and collaborations with leading research institutions. Its approach—harnessing and reinvigorating the body's own T cells—places it at the forefront of personalized immunotherapies in oncology, aiming to redefine treatment strategies for difficult-to-treat cancers and advance the field of immune-based cancer therapeutics.
Pending data availability
Greenhouse Gas (GHG) Emissions Data missing for Iovance Biotherapeutics
We haven’t collected Greenhouse Gas (GHG) Emissions data for Iovance Biotherapeutics yet, or the company
hasn’t made it publicly available.